Company announcement, Helsinki, 2 November 2018 at 4:00 PM
Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD).
In accordance with the invitation to the General Meeting of Nexstim Plc dated 31 October 2018, the shareholders of the Company have been invited to the Extraordinary General Meeting to be held on 21 November 2018 commencing at 12.00 (EET).
The invitation to the meeting includes a writing error stating that the deadline for the registration of a holder of nominee registered shares into the temporary shareholders’ register held by Euroclear Finland Ltd would end already on 9 November 2018 at 10.00 a.m. Notwithstanding the above-mentioned, a holder of nominee registered shares may be registered into such temporary shareholders’ register until 16 November 2018 at 10.00 am.
Consequently, it was resolved to amend section C.2. of the notice to the General Meeting as follows (amendment in bold text):
A holder of nominee registered shares has the right to participate in the Extraordinary General Meeting by virtue of such shares, based on which he/she on the record date of the Extraordinary General Meeting, i.e. on 9 November 2018, would be entitled to be registered in the shareholders’ register of Nexstim held by Euroclear Finland Ltd. The right to participate in the Extraordinary General Meeting requires, in addition, that the shareholder on the basis of such shares has been registered into the temporary shareholders’ register held by Euroclear Finland Ltd at the latest by 16 November 2018 at 10.00 a.m. As regards nominee registered shares this constitutes due registration for the Extraordinary General Meeting.
Helsinki, 2 November 2018
The Board of Directors
Martin Jamieson, CEO
Further information is available on the website www.nexstim.com or by contacting:
Martin Jamieson, Chairman and CEO
+44 771 516 3942
Sisu Partners Oy (Certified Adviser) +358 (0)10 231 4560
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
For more information please visit www.nexstim.com.